Cure My Disease

Don't miss your cure!

 Log in / Sign up

Massive diabetes study launches to uncover Long-Term trends

NCT ID NCT05498974

Knowledge-focused Sponsor: Second Xiangya Hospital of Central South University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is a large registry that will follow 20,000 people with type 1 diabetes across China. It aims to track changes in blood sugar, kidney function, heart health, and emotional well-being over many years. The goal is to better understand how the disease progresses and improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with type 1 diabetes or children and adolescents with diabetes mellitus at age of onset \<= 20 years

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Patients with type 1 diabetes mellitus of any duration; meeting criteria (1) or any of (2) or any of (3) 1. Clinical diagnosis of type 1 diabetes by a specialist 2. Age at onset \< 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide \< 200 pmol/L 3. Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset \<= 20 years, regardless of type and duration of disease. Exclusion Criteria: * For enrolment of patients with T1D, exclusion was made if any of the following criteria were met (not applicable to those with onset under 20 years of age) * No insulin dependence for at least 6 months after diagnosis of diabetes mellitus. * No DKA for 1 month off insulin for those with a history of diabetes \> 1 year. ③ C-peptide \> 800 pmol/L at any time point.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes TYPE1DIABETES

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Gansu Provincial People's Hospital

    RECRUITING

    Lanzhou, Gansu, China

  • Hainan General Hospital

    RECRUITING

    Haikou, Hainan, 570311, China

  • Heji Hospital Affiliated to Changzhi Medical College

    RECRUITING

    Changzhi, Shanxi, China

  • Shenzhen Second People's Hospital

    RECRUITING

    Shenzhen, Guangdong, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    RECRUITING

    Luoyang, Henan, China

  • The First Affiliated Hospital of Nanjing Medical University

    NOT_YET_RECRUITING

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Xinjiang Medical University

    RECRUITING

    Ürümqi, Xinjiang, 830017, China

  • The First People's Hospital of Yunnan

    RECRUITING

    Kunming, Yunnan, China

  • The Second Xiangya Hospital, Central South University

    RECRUITING

    Changsha, Hunan, 410000, China

  • Zhejiang Provincial People's Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

  • the First Affiliated Hospital of Harbin Medical University

    RECRUITING

    Harbin, Heilongjiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.